Tamara Castaño

Dr. Tamara Castaño


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Medicina
Verified
Journal Article
Open access
PDF file
YMYolanda Martínez-Díez
Yolanda Martínez-Díez
AFAida Franganillo-Suárez
Aida Franganillo-Suárez
RSRocío Salgado-Sánchez
Rocío Salgado-Sánchez
MAMireia Atance-Pasarisas
Mireia Atance-Pasarisas
CBCarlos Blas
Carlos Blas
JAJuan Manuel Alonso-Domínguez
Juan Manuel Alonso-Domínguez
Spontaneous remissions (SRs) in acute myeloid leukemia (AML) are infrequent, poorly documented and transient. Similarly, morphological and cytogenetic complete remissions (CR) under azacitidine treatment are scarce. We report a 71-year-old man with a secondary AML arising from essential thrombocythemia (ET), who developed an SR after discontinuation of azacitidine following a respiratory infection (four courses were administered). The distinctive feature of our case is the depth of the achieved CR, documented by next-generation sequencing (NGS) techniques. We also detected persistence of molecular lesions that might already have been present in the previous ET clone. Our patient relapsed 5 months after achieving CR. We conclude that our patient showed a spontaneous remission of his AML rather than an exquisite response to azacitidine. We hypothesize that the concurrent respiratory infection, or any other unknown trigger, might have activated his immune system forcing the leukemic stem cell to enter a quiescent state through a yet unexplained mechanism.

14 May 2024 in Medicina
Verified
Journal Article
Open access
PDF file
TCTamara Castaño
Tamara Castaño
RMRaquel Mata
Raquel Mata
Daniel Lainez-GonzálezDaniel Lainez-González
Daniel Lainez-González
RGRaquel Gonzalo
Raquel Gonzalo
SCSusana Castañón
Susana Castañón
JAJuan Manuel Alonso-Domínguez
Juan Manuel Alonso-Domínguez
Spontaneous remissions (SRs) in blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are infrequent, poorly documented, and transient. We report a 40-year-old man presenting with bycitopenia and soft tissue infection. The bone marrow exhibited 3% abnormal cells. Immunophenotyping of these cells revealed the antigens CD45+ (dim), CD34+, CD117+, CD123+ (bright), HLA-DR+ (bimodal), CD56+ (bright), CD33+, CD13+, CD2+, and CD22+ (dim) and the partial expression of the CD10+, CD36+, and CD7+ antigens. All other myeloid, monocytic, and lymphoid antigens were negative. Genetic studies showed a complex karyotype and mutations in the TP53R337C and KRASG12D genes. On hospital admission, the patient showed a subcutaneous nodule on the right hand and left lower limb. Flow cytometry multiparameter (FCM) analysis showed the presence of 29% abnormal cells with the previously described immunophenotype. The patient was diagnosed with BPDCN. The patient was treated with broad-spectrum antibiotics for soft tissue infection, which delayed therapy for BPDCN. No steroids or chemotherapeutic or hypomethylating agents were administered. His blood cell counts improved and skin lesions disappeared, until the patient relapsed five months after achieving spontaneous remission. About 60% of abnormal cells were identified. No changes in immunophenotype or the results of genetic studies were observed. The patient underwent a HyperCVAD chemotherapy regimen for six cycles. Consolidation therapy was performed via allogeneic bone marrow transplantation with an HLA-unrelated donor. One year after the bone marrow transplant, the patient died due to the progression of his underlying disease, coinciding with a respiratory infection caused by SARS-CoV-2. In the available literature, SRs are often linked to infections or other stimulators of the immune system, suggesting that powerful immune activation could play a role in controlling the leukemic clone. Nevertheless, the underlying mechanism of this phenomenon is not clearly understood. We hypothesize that the immune system would force the leukemic stem cell (LSC) to undergo a state of quiescence. This loss of replication causes the LSC progeny to die off, resulting in the SR of BPDCN.

10 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
IMInés Martínez-Alfonzo
Inés Martínez-Alfonzo
Daniel Lainez-GonzálezDaniel Lainez-González
Daniel Lainez-González
LBLaura Solán Blanco
Laura Solán Blanco
AFAida Franganillo-Suarez
Aida Franganillo-Suarez
JCJosé I. Cornejo
José I. Cornejo
JAJuan Manuel Alonso-Domínguez
Juan Manuel Alonso-Domínguez
Extramedullary involvement of acute myeloid leukemia (AML) is infrequent, and ascitic infiltration is even more unusual. We present a case of a 48-year-old woman diagnosed with NPM1-mutated AML that debuted with ascites, for which morphological studies of the ascitic fluid did not detect leukemic infiltration, maybe due to technical problems in the sample preparation. Multiparameter flow cytometry (MFC) detected a blast population compatible with AML, and allele-specific PCR detected NPM1-mutated transcripts. Body fluid infiltrations are an infrequent initial manifestation or sign of progression in AML. As far as we know, this is the first reported case of an NPM1-mutated AML that debuted with ascites, and also the first description of the utilization of molecular techniques to detect the leukemic origin of the ascites. This case highlights that, given that allele-specific PCR and MFC increase the sensitivity of morphological studies, these techniques should be routinely applied in the study of any kind of effusion detected in an AML patient.

28 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TCTamara Castaño
Tamara Castaño
DLDaniel Láinez-González
Daniel Láinez-González
JSJuana Serrano
Juana Serrano
MAMireia Atance
Mireia Atance
RMRaquel Mata
Raquel Mata
JAJuan Manuel Alonso-Domínguez
Juan Manuel Alonso-Domínguez
The bone marrow microenvironment influences acute myeloid leukemia (AML) progression. Mesenchymal stem cell–like (MSC-l) populations may exert tumor-modulating effects, but their prognostic role remains uncertain. We retrospectively analyzed 65 adult AML patients (excluding acute promyelocytic leukemia) treated with intensive chemotherapy between 2017 and 2024 at four Spanish institutions. MSC-l cells were identified in BM aspirates at end of treatment by multiparameter flow cytometry (CD13bright/CD45low/CD34neg/CD117neg/CD11bneg/CD16neg/CD71neg/CD64neg). Patients were stratified using a 0.265%cutoff (MSC-lHIGH ≥ 0.265% and MSC-lLOW < 0.265%). Survival was assessed with Kaplan–Meier and Cox regression, adjusting for age and ELN 2017 risk. MSC-lHIGH patients had inferior overall survival (OS) (median 0.66 years vs. not reached; P < 0.001) and relapse-free survival (RFS) (median 1.27 years vs. 1.49 years; P = 0.027). These associations persisted across ELN risk groups. Multivariate analysis confirmed MSC-lHIGH status as an independent predictor of worse OS (HR = 6.43; 95% CI 2.53–16.33; P < 0.001) and RFS (HR = 4.8; 95% CI 1.71–13.47; P = 0.003). MSC-l levels were lower in patients receiving myeloablative conditioning compared with non-transplanted patients, suggesting transplant intensity may influence MSC dynamics. Higher post-treatment MSC-l proportions are associated with poorer survival, independent of ELN risk and age, supporting their potential as a prognostic biomarker in AML.